Downregulation of vasohibin-2, a novel angiogenesis regulator, suppresses tumor growth by inhibiting angiogenesis in endometrial cancer cells

Oncology Letters

Volumn 5, Issue 3, 2013, Pages 1058-1062

  Koyanagi, Takahiro ^a,b   Saga, Yasushi ^a   Takahashi, Yoshifumi ^a,b   Suzuki, Yasuhiro ^b   Suzuki, Mitsuaki ^a   Sato, Yasufumi ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

Endometrial cancer; Endothelial cells; Molecular targeted therapy; Tumor angiogenesis; Vasohibin 2

Indexed keywords

ANGIOGENIC FACTOR; UNCLASSIFIED DRUG; VASOHIBIN 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

EID: 84872704308     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1119     Document Type: Article

References (26)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer Statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Wolfson AH, Sightler SE and Markoe AM: The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol 45: 142-146, 1992.
3. Kamat AA, Merritt WM, Coffey D, et al: Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13: 7487-7495, 2007.
4. Kowanetz M and Ferrara N: Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 12: 5018-5022, 2006.
5. Ortega J, Vigil CE and Chodkiewicz C: Current progress in targeted therapy for colorectal cancer. Cancer Control 17: 7-15, 2010.
6. Koutras AK, Fountzilas G, Makatsoris T, Peroukides S and Kalofonos HP: Bevacizumab in the treatment of breast cancer. Cancer Treat Rev 36: 75-82, 2010.
7. Tamaskar I and Pili R: Update on novel agents in renal cell carcinoma. Expert Rev Anticancer Ther 9: 1817-1827, 2009.
8. Norden AD, Drappatz J and Wen PY: Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 5: 610-620, 2009.
9. Watanabe K, Hasegawa Y, Yamashita H, et al: Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest 114: 898-907, 2004.
10. Kimura H, Miyashita H, Suzuki Y, et al: Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood 113: 4810-4818, 2009.
11. Xue X, Gao W, Sun B, et al: Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. Oncogene: May 21, 2012 (Epub ahead of print).
12. Takahashi Y, Koyanagi T, Suzuki Y, et al: Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis. Mol Cancer Res: Jul 23, 2012 (Epub ahead of print).
13. Kuramoto H, Tamura S and Notake Y: Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol 114: 1012-1019, 1972.
14. Suzuki M, Kuramoto H, Hamano M, Shirane H and Watanabe K: Effects of oestradiol and progesterone on the alkaline phosphatase activity of a human endometrial cancer cell-line. Acta Endocrinol (Copenh) 93: 108-113, 1980.
15. Nishida M: The Ishikawa cells from birth to the present. Hum Cell 15: 104-117, 2002.
16. Miyagishi M and Taira K: Strategies for generation of an siRNA expression library directed against the human genome. Oligonucleotides 13: 325-333, 2003.
17. Yamamoto O, Hamada T, Tokui N and Sasaguri Y: Comparison of three in vitro assay systems used for assessing cytotoxic effect of heavy metals on cultured human keratinocytes. J UOEH 23: 35-44, 2001.
18. Suzuki Y, Kobayashi M, Miyashita H, Ohta H, Sonoda H and Sato Y: Isolation of a small vasohibin-binding protein (SVBP) and its role in vasohibin secretion. J Cell Sci 123: 3094-3101, 2010.
19. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
20. Ferrara N: Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 29: 789-791, 2009.
21. McMeekin DS, Sill MW, Benbrook D, et al; Gynecologic Oncology Group: A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol 105: 508-516, 2007.
22. Sanseverino F, Santopietro R, Torricelli M, et al: pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade. Cancer Biol Ther 5: 84-88, 2006.
23. Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M and Yoshihara T: Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol 80: 181-188, 2001.
24. Cerezo L, Cardenes H and Michael H: Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications. Clin Transl Oncol 8: 231-241, 2006.
25. Saranadasa M and Wang ES: Vascular endothelial growth factor inhibition: conflicting roles in tumor growth. Cytokine 53: 115-129, 2011.
26. Korpal M and Kang Y: The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 5: 115-119, 2008.